Cardio Diagnostics Secures CMS Pricing for PrecisionCHD and Epi+Gen CHD Tests

Cardio Diagnostics Advances Cardiovascular Care with CMS Pricing Determination

Cardio Diagnostics Holdings, Inc., a pioneering company in AI-driven precision cardiovascular medicine, celebrates a significant milestone as the Centers for Medicare & Medicaid Services (CMS) finalize pricing determinations for its innovative testing products, PrecisionCHD and Epi+Gen CHD. This final ‘gapfill’ pricing determination, which takes effect for claims on or after January 1, 2025, allows Medicare contractors to establish pricing based on actual cost data submitted by Cardio Diagnostics. This decision follows a preliminary determination made in August 2024, and the company is required to report the preliminary gapfill pricing to CMS by April 1, 2025.

The implications of this pricing determination are substantial for Cardio Diagnostics and the broader healthcare landscape. CEO and Co-Founder Meesha Dogan, Ph.D., underscores the importance of this achievement for enhancing the risk assessment, diagnosis, management, and ongoing monitoring of coronary heart disease (CHD) among Medicare patients. Given that cardiovascular disease is the leading cause of death in the United States, responsible for over 700,000 fatalities in 2022, the introduction of these advanced diagnostic tools is timely and essential. PrecisionCHD utilizes AI to analyze genetic and epigenetic markers, providing a comprehensive approach to diagnosing CHD, while the Epi+Gen CHD test evaluates the three-year risk of CHD events, including heart attacks.

As Cardio Diagnostics sets its sights on revolutionizing cardiovascular care, the company’s proprietary AI-driven Integrated Genetic-Epigenetic Engine positions it at the forefront of medical technology. With the recent receipt of CPT Proprietary Laboratory Analysis codes from the American Medical Association, effective April 1, 2024, the company further solidifies its commitment to improving patient outcomes through innovative testing solutions. The advancements in their testing capabilities not only promise to enhance the prevention and detection of cardiovascular disease but also signify a crucial step toward better management strategies for patients at risk.

In addition to the CMS pricing announcement, Cardio Diagnostics continues to focus on expanding its influence in the cardiovascular diagnostics market. The company's commitment to integrating advanced AI technology with genetic insights exemplifies its dedication to addressing the pressing needs posed by CHD. With the healthcare industry increasingly leaning towards precision medicine, Cardio Diagnostics is positioned to make a substantial impact on patient care and outcomes in the coming years.